PT946731E - Estirpes de vih não m e não o, os seus fragmentos e aplicações - Google Patents

Estirpes de vih não m e não o, os seus fragmentos e aplicações Download PDF

Info

Publication number
PT946731E
PT946731E PT97950245T PT97950245T PT946731E PT 946731 E PT946731 E PT 946731E PT 97950245 T PT97950245 T PT 97950245T PT 97950245 T PT97950245 T PT 97950245T PT 946731 E PT946731 E PT 946731E
Authority
PT
Portugal
Prior art keywords
strain
ybf30
hiv
regard
group
Prior art date
Application number
PT97950245T
Other languages
English (en)
Inventor
Phil Mauclere
Ibtissam Loussert-Ajaka
Francois Simon
Sentob Saragosti
Francoise Barre-Sinoussi
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris filed Critical Pasteur Institut
Publication of PT946731E publication Critical patent/PT946731E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • G01N33/56988HIV or HTLV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
PT97950245T 1996-12-09 1997-12-08 Estirpes de vih não m e não o, os seus fragmentos e aplicações PT946731E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615087A FR2756843B1 (fr) 1996-12-09 1996-12-09 Souches de vih-1 non-m non-o, fragments et applications

Publications (1)

Publication Number Publication Date
PT946731E true PT946731E (pt) 2009-05-14

Family

ID=9498464

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97950245T PT946731E (pt) 1996-12-09 1997-12-08 Estirpes de vih não m e não o, os seus fragmentos e aplicações

Country Status (14)

Country Link
US (4) US6509018B1 (pt)
EP (1) EP0946731B1 (pt)
JP (1) JP2000515768A (pt)
CN (1) CN1244896B (pt)
AT (1) ATE422544T1 (pt)
AU (1) AU737857B2 (pt)
BR (1) BRPI9713891B8 (pt)
CA (1) CA2274490C (pt)
DE (1) DE69739251D1 (pt)
DK (1) DK0946731T3 (pt)
ES (1) ES2323604T3 (pt)
FR (1) FR2756843B1 (pt)
PT (1) PT946731E (pt)
WO (1) WO1998026075A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2001004361A2 (en) * 1999-07-09 2001-01-18 Gen-Probe Incorporated Detection of hiv-1 by nucleic acid amplification
DE19936003A1 (de) * 1999-08-03 2001-02-15 Dade Behring Marburg Gmbh Lentivirus aus der Gruppe der Immunschwächeviren der Drillaffen(mandrillus leucophaeus) und ihre Verwendung
WO2004092724A2 (en) * 2003-04-11 2004-10-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Multiple antigenic peptide assay for detection of hiv or siv type retroviruses
ES2572132T3 (es) * 2004-08-17 2016-05-30 Roussy Inst Gustave Nef del VIH mutada para modular la inmunidad
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc HETERO DUPLEX TRACKING TEST
RU2355763C2 (ru) * 2006-09-13 2009-05-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот
JP2010521156A (ja) * 2007-03-16 2010-06-24 454 ライフ サイエンシーズ コーポレイション Hiv薬物耐性バリアントの検出のためのシステムおよび方法
WO2009126517A2 (en) * 2008-04-09 2009-10-15 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1
US9650668B2 (en) 2008-09-03 2017-05-16 Nabsys 2.0 Llc Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
JP5998148B2 (ja) 2010-11-16 2016-09-28 ナブシス 2.0 エルエルシー ハイブリダイズされたプローブの相対位置を検出することによる生体分子のシークエンシングのための方法
US11274341B2 (en) 2011-02-11 2022-03-15 NABsys, 2.0 LLC Assay methods using DNA binding proteins
US9914966B1 (en) 2012-12-20 2018-03-13 Nabsys 2.0 Llc Apparatus and methods for analysis of biomolecules using high frequency alternating current excitation
US10294516B2 (en) 2013-01-18 2019-05-21 Nabsys 2.0 Llc Enhanced probe binding

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3588254T2 (de) * 1984-10-18 2008-06-26 Institut Pasteur GAG-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
WO1992006990A1 (en) * 1990-10-17 1992-04-30 The United States Of America, Represented By The Secretary, United States Department Of Commerce Molecular clones of hiv-1 and uses thereof
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
US5945301A (en) * 1995-09-29 1999-08-31 Chugai Seiyaku Kabushiki Kaisha Kinase in TGF-β family signal transduction system
US5994123A (en) * 1996-08-09 1999-11-30 Regents Of University Of Minnesota Sugarcane bacilliform virus promoter

Also Published As

Publication number Publication date
US7534877B2 (en) 2009-05-19
CA2274490A1 (fr) 1998-06-18
FR2756843B1 (fr) 1999-01-22
US20030157660A1 (en) 2003-08-21
CA2274490C (fr) 2013-02-12
EP0946731B1 (fr) 2009-02-11
US20100184014A1 (en) 2010-07-22
JP2000515768A (ja) 2000-11-28
WO1998026075A1 (fr) 1998-06-18
BRPI9713891B8 (pt) 2021-07-06
DK0946731T3 (da) 2009-06-22
US8227185B2 (en) 2012-07-24
US7030234B2 (en) 2006-04-18
US6509018B1 (en) 2003-01-21
BRPI9713891B1 (pt) 2015-08-18
FR2756843A1 (fr) 1998-06-12
DE69739251D1 (de) 2009-03-26
EP0946731A1 (fr) 1999-10-06
ES2323604T3 (es) 2009-07-21
BRPI9713891A (pt) 2000-02-29
AU737857B2 (en) 2001-08-30
CN1244896A (zh) 2000-02-16
AU5327298A (en) 1998-07-03
ATE422544T1 (de) 2009-02-15
CN1244896B (zh) 2011-06-22
US20070190524A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
PT946731E (pt) Estirpes de vih não m e não o, os seus fragmentos e aplicações
AU3762889A (en) Hiv-3 retrovirus and its use
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
EP0752887A4 (en) RECOMBINANT IMMUNE WEAKNESS POX VIRUS
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
AU4712397A (en) Lentiviral vectors
EP1372710A4 (en) MVA-EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES
WO2006013106A3 (en) Vaccine for prevention and treatment of hiv-infection
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
CA2328404A1 (en) Novel lentiviral packaging cells
DE69535500D1 (de) Nicht pathogene stämme des hiv-1
FR2731013B1 (fr) Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
ES2012129A6 (es) Un metodo para la obtencion de fragmentos de cd4 humana biologicamenteactivos.
EP0404625A3 (fr) Séquences oligonucléotidiques pour l'amplification du génome des rétrovirus du type HIV-2 et SIV, et leurs applications au diagnostic in-vitro des infections dûes à ces virus
WO2008151633A3 (en) Vectors for vaccines against lentivirus infections
IGARASHI et al. Isolation and genomic analysis of human T lymphotropic virus type II from Ghana
WO2002020571A3 (en) Attenuated hiv strains and use thereof
Whitcomb et al. The sequence of human immunodeficiency virus type 2 circle junction suggests that integration protein cleaves the ends of linear DNA asymmetrically
Artenstein et al. Sequence Note: Sequences and Phylogenetic Analysis of the nef Gene from Thai Subjects Harboring Subtype E HIV-1
SHEREFA et al. Sequence Note: Full-Length Sequence of Human Immunodeficiency Virus Type 1 Subtype A, Recombined with Subtype C in the env V3 Domain
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.